ACTON, Mass., May 19, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform ...
This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bluejay ...
Neonatal sepsis is a leading cause of death for newborns Testing IL-6 can indicate a neonatal sepsis infection earlier than other biomarkers Earlier diagnosis of neonatal sepsis can lead to improved ...
ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and ...
The company’s first product candidate is an IL-6 Test for sepsis. The company emphasized that the Symphony System remains under development and subject to further validation and regulatory review.
(RTTNews) - Roche (RHHBY) said the Elecsys IL-6 immunoassay has become the first IL-6 test to have a certified claim for use in diagnosis of neonatal sepsis, in countries accepting the CE Mark. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback